Therefore, we propose that metabolic reprogramming through the p62–Keap1–Nrf2 pathway stimulates growth of HCC cells and increases their tolerance to anti-cancer drugs (Fig. 10g). The gene discussed is SQSTM1; the disease is hepatocellular carcinoma.